Muhlenkamp & Co’s Biogen BIIB Stock Holding History

Muhlenkamp & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,000	Closed	-$939K	–	74
2017 Q3	$939K	Hold	3,000	–	–	0.3%	39
2017 Q2	$814K	Hold	3,000	–	–	0.26%	41
2017 Q1	$820K	Hold	3,000	–	–	0.25%	43
2016 Q4	$851K	Hold	3,000	–	–	0.27%	42
2016 Q3	$939K	Hold	3,000	–	–	0.35%	33
2016 Q2	$725K	Hold	3,000	–	–	0.28%	36
2016 Q1	$781K	Buy	+3,000	New	+$792K	0.32%	33

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Muhlenkamp & Co's BIIB Position: Q3 2021 in Review

Muhlenkamp & Co sold out of Biogen (BIIB) in Q3 2021, closing a stake of 18,218 shares — an estimated $6.31M sold.

Muhlenkamp & Co first reported a position in BIIB in Q1 2016 and held it in 20 quarters. The position peaked at $7.86M in Q4 2017. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

Muhlenkamp & Co reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
Muhlenkamp & Co sold 18,218 Biogen shares in Q3 2021, an estimated $6.31M.
Muhlenkamp & Co first reported a position in Biogen in Q1 2016 and held it in 20 quarters.
Muhlenkamp & Co's Biogen position peaked at $7.86M in Q4 2017.
1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Muhlenkamp & Co's 13F filing for Q3 2021, filed 10 Dec 2021.